Abstract
We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.
Keywords: Hepatitis B virus, hepatitis C virus, reverse seroconversion
Clinical Pearls
Unique Features of the Case: Reverse HBV seroconversion occurred in an 88-year-old woman more than a decade after HCV cure, despite previously resolved HBV infection, previously documented high anti-HBs levels, and no identifiable immunosuppression or trigger.
Primary Lesson for Clinicians: HBV reactivation can occur years after apparent clearance even without immunosuppression. Long-term vigilance is warranted in patients with resolved HBV, particularly older individuals and those with prior HCV coinfection.
Introduction
Reverse seroconversion of hepatitis B virus (HBV), defined as reappearance of hepatitis B surface antigen (HBsAg) in a previously resolved infection, is a well-documented phenomenon in immunocompromised patients. However, its occurrence in immunocompetent individuals without a clear trigger is extremely rare. In patients with HBV-hepatitis C virus (HCV) coinfection, suppression of HBV replication by HCV has been observed. After HCV eradication, latent HBV may reactivate, though this typically occurs within months.[1] We report an unusual case of delayed HBV reverse seroconversion over a decade after HCV cure, presenting as decompensated cirrhosis. The patient has provided informed consent for publication of the case.
Case Report
An 88-year-old East Asian woman with a remote history of HCV genotype 1b, successfully treated with ledipasvir/sofosbuvir 10 years previously, was referred to the emergency department with progressive bilateral lower limb edema and increasing abdominal girth. Outpatient records from 10 years ago confirmed negative HBsAg, positive hepatitis B core antibody, and high-titer hepatitis B surface antibody (anti-HBs) of 180.5 mIU/mL, consistent with resolved HBV infection and a protective anti-HBs response. She had no recent history of immunosuppression, chemotherapy, or systemic illness. Her home medications included antihypertensives, a bisphosphonate, and a proton pump inhibitor. She denied alcohol or drug use.
On presentation, she was noted to have scleral icterus, pitting edema up to the thighs, and mild abdominal distension. Laboratory workup revealed alanine aminotransferase 494 U/L, aspartate aminotransferase 641 U/L, alkaline phosphatase 120 U/L, gamma-glutamyl transferase 144 U/L, total bilirubin 56 µmol/L, albumin 20 g/L, and international normalized ratio 1.4. Abdominal ultrasound and computed tomography imaging showed a nodular liver contour and perihepatic ascites, without focal hepatic lesions or thrombosis. Esophagogastroduodenoscopy revealed no esophageal or gastric varices.
Notably, viral serology revealed newly positive HBsAg and HBeAg, with an HBV viral load of 797,000 IU/mL. HCV RNA remained undetectable. Autoimmune, vascular, and metabolic workup for alternative causes of liver disease was unremarkable. There was no prior history of chronic HBV infection. A basic immunodeficiency workup, including complete blood count, hemoglobin A1c, immunoglobulin levels, and HIV serologies, was also unremarkable.
She was diagnosed with HBV reactivation with reverse seroconversion, presenting with decompensated cirrhosis. She was initially treated with tenofovir, but this was switched to entecavir because of underlying osteoporosis. Diuretics were initiated for ascites and peripheral edema, and she was discharged in stable condition.
At outpatient follow-up, she showed progressive clinical improvement. Five months later, her liver enzymes had normalized, and HBV viral load had decreased to <100 IU/mL, though remained detectable at 70 IU/mL. Diuretics were discontinued, and she remained stable on entecavir with ongoing laboratory and imaging surveillance. Trends in HBV DNA and liver biochemistry are shown in Figure 1.
Figure 1.

Trends in hepatitis B virus DNA and liver biochemistry.
Discussion
Reverse seroconversion of HBV is defined as the reappearance of HBsAg in individuals with previously resolved infection, which is most commonly associated with immunosuppressive states, such as chemotherapy, biologic agents, or organ transplantation. However, there is only a limited number of published cases in the literature reporting reverse seroconversion in patients without overt immunosuppression, particularly among elderly or medically frail individuals, as outlined in Table 1.
Table 1.
Literature review of case reports of HBV reverse seroconversion in the absence of immunosuppression
| Parameter | Current Case Report | Freudiger et al. (2004)[2] | Deroux et al. (2012)[3] | Kamitsukasa et al. (2015)[5] | Kim et al. (2018)[6] | Ozturk Cerik et al. (2025)[4] |
|---|---|---|---|---|---|---|
| Age | 88 | 73 | 84 | 74 | 82 | 81 |
| Sex | Female | Female | Male | Male | Male | Female |
| Baseline HBsAg | Negative | Negative | Negative | Negative | Negative | Negative |
| Baseline anti-HBs (mIU/mL) | 180.5 | 13 | 212 | 12.7 | Positive (titer not reported) | 77.5 |
| Baseline Anti-HBc | Positive | Positive | Positive | Not available | Not available | Positive |
| Trigger | None identified | None identified | Ischemic stroke | Post-CABG | None identified | Hemorrhagic stroke |
| Comorbidities/Clinical characteristics | Advanced age, remote cured HCV | Advanced age, CKD with hemodialysis, COPD, HTN, PVD, osteoporosis | Advanced age, diabetes, HTN, IHD, COPD, sleep apnea | Not reported, advanced age | Iron deficiency anemia, vertebroplasty 5 years ago | Advanced age, COPD, HTN, diabetes |
Anti-HBc: Hepatitis B core antibody; Anti-HBs: Hepatitis B surface antibody; COPD: Chronic obstructive pulmonary disease; HTN: Hypertension; PVD: Peripheral vascular disease; CKD: Chronic kidney disease; HCV: Hepatitis C virus; IHD: Ischemic heart disease; CABG: Coronary artery bypass grafting.
Several cases have documented spontaneous HBV reactivation in the absence of identifiable triggers. Freudiger et al.[2] reported a 73-year-old hemodialysis patient who developed reverse seroconversion without immunosuppressive therapy, suggesting that uremia and age-related immune decline may have contributed. Other reports have implicated acute physiological stress as a trigger. For example, Deroux et al.[3] and Ozturk Cerik et al.[4] reported HBV reactivation following ischemic and hemorrhagic strokes, respectively, hypothesizing that neurologic injury may induce transient immune dysregulation. Kamitsukasa et al.[5] described a patient who reactivated after coronary artery bypass grafting, again without pharmacologic immunosuppression. Lastly, Kim et al.[6] presented a case of spontaneous reactivation in an elderly male with no evident trigger, further supporting immune senescence as an independent risk factor.
Our patient shared several features with previously reported cases, including advanced age, no recent immunosuppression, and a long-standing resolved HBV infection with anti-HBs positivity. Her case is unique in that there was no identifiable trigger, she had markedly high anti-HBs, and she was otherwise healthy with minimal medical complexity compared to other reported cases.
Importantly, she also had a history of HCV coinfection that had been successfully treated 10 years previously. HBV–HCV coinfection is not uncommon, given the shared routes of transmission, and is clinically important because it often results in a more severe course of liver disease, faster progression to cirrhosis, and an increased risk of hepatocellular carcinoma compared to monoinfection.[7] At a virological level, HCV often exerts a suppressive effect on HBV replication through direct viral interactions. Clearance of HCV with direct-acting antivirals (DAAs) can remove this suppressive pressure, leading to latent HBV reactivation, which, in rare cases, can progress to fulminant hepatitis requiring a transplant.[1] Conversely, HBV can sometimes suppress HCV replication, though this phenomenon is less well described and less common.[8]
Given these interactions, the European Association for the Study of the Liver (EASL) recommends HBV screening in all patients undergoing HCV treatment, with consideration of prophylactic or preemptive HBV antiviral therapy in those at risk of reactivation who do not otherwise meet criteria for chronic HBV treatment.[9] Most reported cases of HBV reactivation after HCV cure occur within months of DAA therapy, underscoring the importance of close monitoring after HCV eradication. EASL recommends continuing nucleos(t)ide analogue therapy for at least 12 weeks following HCV treatment.[9] In our patient, however, reactivation occurred more than a decade after HCV cure, making it unlikely to be directly attributable to the loss of HCV-mediated suppression. Nevertheless, her history of dual infection may have predisposed her to late reactivation in the setting of immune senescence. This highlights the clinical importance of long-term vigilance in patients with resolved HBV, even when HCV has been eradicated.
Conclusion
In summary, this case adds to the sparse literature showing that reverse HBV seroconversion can occur spontaneously in immunocompetent individuals, particularly the elderly. We suspect that many more cases have been unreported and perhaps even unrecognized. Clinicians should maintain long-term vigilance in patients with resolved HBV infection, especially those with prior HCV coinfection, as immune senescence or subtle physiologic stressors may precipitate reactivation even years after apparent viral control.
Footnotes
How to cite this article: Zhu K, Wu E, Tam B, Yoshida EM, Kwan P. Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review. Hepatology Forum 2026; 7(4):420–423.
Ethics Committee Approval
This is a single case report, and therefore ethics committee approval was not required in accordance with institutional policies.
Informed Consent
The patient has provided informed consent for publication of the case.
Conflict of Interest
All authors declare no conflicts of interest.
Financial Disclosure
The authors declared that this study has received no financial support.
Use of AI for Writing Assistance
The authors declared that artificial intelligence was not used in the study.
Author Contributions
Concept: KZ, EMY, PK; Design: EMY, PK; Supervision: EMY, PK; Analysis and/or Interpretation: KZ, EW, BT, EMY, PK; Literature Search: KZ, EW, BT; Writing: KZ, EW, BT; Critical Review: EMY, PK.
Peer-review
Externally peer-reviewed.
References
- 1.Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66(1):13–26. doi: 10.1002/hep.29109. [DOI] [PubMed] [Google Scholar]
- 2.Freudiger H, Sitavanc R. Reverse seroconversion of hepatitis B in a haemodialysis patient. Nephrol Dial Transplant. 2004;19(1):238–241. doi: 10.1093/ndt/gfg448. [DOI] [PubMed] [Google Scholar]
- 3.Deroux A, Larrat S, Hilleret MN, Baccard M, Qin W, Billet G, et al. Case report: Detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident. J Med Virol. 2012;84(12):1897–1900. doi: 10.1002/jmv.23420. [DOI] [PubMed] [Google Scholar]
- 4.Ozturk Cerik H, Aldemir O. Spontaneous reactivation of resolved HBV infection in the absence of immunosuppression: case report and literature review. Diagn Microbiol Infect Dis. 2025;111(3):116675. doi: 10.1016/j.diagmicrobio.2024.116675. [DOI] [PubMed] [Google Scholar]
- 5.Kamitsukasa H, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87(4):589–600. doi: 10.1002/jmv.24115. [DOI] [PubMed] [Google Scholar]
- 6.Kim DH, Kim SB. Hepatic failure by spontaneous reactivation of hepatitis B virus without a trigger factor in a patient with anti-HBs. Case Rep Gastroenterol. 2018;12(2):286–291. doi: 10.1159/000490099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, El-Serag HB, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014;60(6):1871–1878. doi: 10.1002/hep.27337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Li Y, Yang Y, Li T, Wang Z, Gao C, Deng R, et al. Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfection. J Virol. 2023;97(10):e0109023. doi: 10.1128/jvi.01090-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.European Association for the Study of the Liver EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502–583. doi: 10.1016/j.jhep.2025.03.018. [DOI] [PubMed] [Google Scholar]
